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nimal models of psychiatric diseases attempt to
capture various features of the human condition,from
behavioral and physiological changes that are indicative
of the emotional state to the etiology of the disease and
the effects of therapeutic interventions. According to
McKinney,
1 animal models are “experimental prepara-
tions developed in one species for the purpose of study-
ing phenomena occurring in another species.In the case
of animal models of human psychopathology one seeks
to develop syndromes in animals which resemble those
of humans in certain ways in order to study selected
aspects of human psychopathology.”Later,other authors
(eg,ref 2) proposed additional criteria that animal mod-
els need to fulfill.Suitable research models ought to dis-
play clear face validity (isomorphism),predictive validity
(pharmacological correlation), and construct validity
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An impressive number of animal models to assess depression and anxiety are available today. However, the rela-
tionship between these models and the clinical syndromes of depression and anxiety is not always clear. Since human
anxiety disorders represent a multifactorial phenomenon frequently comorbid with major depression and/or other
psychiatric problems, the chance of creating animal models which consistently reflect the human situation is quite
poor. When using experimental models to understand homologies between animal and human behavior, we have
to consider the context in which an animal is investigated, and both the functional significance and relevance of the
behavioral parameters that are quantified. Moreover, gender and interindividual and interspecies variabilities in
behavioral responses to the test situation and in the sensitivity to pharmacological treatments are potential sources
for confounding results. In the past, these aspects have been often neglected in preclinical approaches to behavioral
pharmacology and psychopharmacology. A pragmatic approach of combined preclinical and clinical efforts is neces-
sary to imitate one or more aspects relevant to pathological anxiety disorders and depression. The resulting mod-
els may identify central nervous processes regulating defined behavioral output, with the potential to develop more
effective treatments.    
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ical mechanisms). Currently, the third criterion is
regarded as having heuristic value because the central
nervous processes that lead to anxiety/depression still
have to be elucidated;therefore this criterion is regarded
as desirable,but not essential.
3Thus,in an ideal and per-
fect model one would like to have causative conditions,
symptom profiles,and treatment responses identical to
those seen in the human disease state.
Any animal model of depression, or of antidepressant
activity, must account for the considerable symptom
overlap between major depressive disorder (MDD) and
anxiety disorders,eg,sleep disturbances,agitation,rest-
lessness,irritability,difficulty concentrating,loss of con-
trol,fatigue,fear,distress and,of course,anxiety.Indeed,
comorbidity of anxiety disorders and MDD is the rule
rather than the exception (eg, refs 4-6)with more than
80% of adults with depression also having significant
symptoms of anxiety.
7 Furthermore,most of the existing
antidepressants successfully ameliorate anxiety as a com-
ponent of depression (eg,ref 8).
In this article we will discuss relevant animal models that
have been developed and are used to enhance our under-
standing of the pathophysiology of the most common psy-
chiatric disorders,depression and anxiety,and to guide the
development of novel and more effective treatments.
Animal models of depression
The diagnosis of depressive illness and anxiety relies
almost exclusively on observation of behavior and inter-
personal relations,and on reported feelings and beliefs
of the patient.
9Therefore,several recent reviews claim
that it is difficult to develop a true animal model of
depressive disorders because mental illness may be a
uniquely human condition.In particular,typical symp-
toms in depressed patients,such as recurring thoughts of
suicide or death,or excessive thoughts of guilt,are impos-
sible to model in animals. The creation of reasonably
valid animal models of psychiatric diseases has been dif-
ficult,mainly due to both the verbal and personal nature
of the symptoms to be modeled,eg,sadness or delusions,
as well as the lack of clear etiological factors which can
be used to design valid models.Moreover,unlike the sit-
uation with other neurological disorders such as
Alzheimer’s disease or Parkinson’s disease,we still have
only a vague idea about the pathophysiological processes
that underlie depression.
The earliest models of depressive states in animals were
based on maternal separation experiments in infant non-
human primates.
10 In rodents,manipulation of early life
environment such as prenatal stress and maternal sepa-
ration produces bio behavioral changes that persist well
into adulthood, representing a risk factor for psy-
chopathology.
11Another behavioral approach to simulate
a human depressive state in animals is the learned help-
lessness model.Originally described in dogs subjected to
inescapable electric shock,
12 this model has received con-
siderable attention in studies of “depression”in mice and
rats (for review see refs 13,14).Limitations of the help-
lessness test as consequence of foot shock are that the
test is difficult to replicate between laboratories
15 and
that it cannot be routinely used in a number of countries
because of ethical or regulatory supervision.
14
The chronic mild stress model is based on exposure of
animals (usually rats) to uncontrollable stressors.
Animals are subjected,in succession,to a range of mild
stressors such as disrupted light-dark cycle,wet bedding,
having an intruder rat placed in the home cage,or hav-
ing the home cage tilted at an angle for 1 to 2 days.
16The
complex procedures of this model almost ensure that
every laboratory will have at least slightly different
experimental setups, and consequently, also different
interpretations of the protocols.
14
Among the most potent factors known to trigger or
induce depressive episodes are stressful life events.
17-20
Stress is considered to perturb the homeostasis of an
organism in a way that can lead to a long-lasting imbal-
ance in neurotransmitter,neuroendocrine,and hormonal
systems and thus finally to a psychiatric disease. The
stress hypothesis of mood disorders has stimulated the
development of a number of putative animal models of
depression.
2,21 Loss of rank and/or social status in humans
is one example of loss experiences which are increasingly
recognized as specific type of “life event”associated with
a great risk of depression.
22A number of behavioral mod-
els have sought to stimulate or model depression by
manipulating social relationships in animals, and new
powerful animal models using chronic psychosocial per-
turbations as stressors have been established (eg,ref 23).
In recent years,our group has provided increasing evi-
dence that chronic psychosocial stress in the male tree
shrew (Tupaia belangeri) represents a natural and valid
paradigm for studying the behavioral, endocrine, and
neurobiological changes that may underlie stress-related
disorders such as depression.
24 Recently,our group has
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324described and validated a new model of chronic social
stress in rats
25 based on the resident–intruder paradigm
originally described by Miczek
26 and Koolhaas et al.
27This
model,in which depressive-like behavior can be normal-
ized by antidepressants, provides the opportunity to
study gene expression in distinct brain areas.
28,29Although
the relevant literature is constantly expanding,one can
already summarize today that models of social stress
greatly increased our understanding of processes that
take place in the brain during depressive-like states of an
animal. Also the understanding of antidepressant-
induced processes has greatly increased in the past years
(eg,ref 30).
A summary of animal models of depression that are clas-
sified according to type and sensitivity to chronic drug
treatment is presented in Table I.According to Willner
and Mitchell,
31 the diathesis models summarize those par-
adigms that involve a genetically determined predisposi-
tion for the depressive illness, whereas in mere stress
models external stimuli are the only factors triggering
changes in behavior and physiology. Social dominance
models are those that use natural (social) stressors and
are considered as a subset of the stress models.
Many of the paradigms addressed above are more cor-
rectly described as models of stress rather than models
of depression.Not all responses to stress are maladap-
tive,because the stress response may also fulfill adaptive
or protective functions.Therefore,to truly model depres-
sion,other factors such as the genetic background that
might cause a predisposition for the disease must also be
taken into consideration. However, studies looking at
stressful early life experiences and the type of stress-
responsiveness later in life highlight a key area.They may
help to understand the processes that in conjunction with
environmental stress can lead to depression in some indi-
viduals but not in others.
With the emergence of specific genetic factors more
defined models may be created in the near future.In the
case of major depressive illness,we know that genetic fac-
tors can only account for about 30% of the variance,and
environmental factors clearly play a major role in induc-
ing the illness.
32 However,the development of models of
depression based on the interaction between stress and
genetic vulnerability appears plausible. Generation of
specific strains or lines of rats or mice may be advanta-
geous.Studies in knockout models with a mutation in a
single gene may be of limited usefulness because of con-
founding factors such as developmental adaptational
processes.Conditional knockouts may be considered as
an improvement,but they also can inform us only about
the role of a single gene.Therefore, the more complex
models involving the interaction of genes and environ-
ment could supposedly yield more useful information.
Validity of animal models
The importance of chronic drug treatment
Pharmacological tests and models sensitive to acute drug
treatment are not included in this overview.These mod-
els,perhaps more appropriately called “screens,”
33 have
been designed to detect most existing antidepressants.
The mechanism(s) of action by which test compounds
produce positive results in such screens may not be iden-
tical,or even not similar to the mechanisms underlying
their clinical effects.One might have concerns about how
drugs are applied to animals in preclinical experiments
when comparing the routes of administration with those
generally used in clinical settings. Many screens try to
detect antidepressant-like activity quite quickly,within
minutes or hours, and the drugs are given prior to the
testing, thus producing a behavioral alteration rather
than preventing a disease-induced type of behavior.It is
obvious that such an approach bears no similarity to the
clinical situation where drugs are administered only after
disease symptoms have already appeared,and where a
delayed onset of therapeutic effects for at least 2 to 3
weeks has to be expected.In light of such data,we would
suggest that one important characteristic factor for ani-
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Table I. Animal models of depression.
Model type Sensitive to chronic drug treatment
Diathesis models
Lesion model Olfactory bulbectomy
Genomic model HPA axis transgenes
Genetic models Flinders sensitive line
Developmental models Prenatal or neonatal stress
Stress models
Acute stress Learned helplessness
Restraint stress
Chronic stress Chronic mild stress
Restraint stress
Social dominance models
Social separation Neonatal / adult isolation
Social defeat Resident-intruder
Social hierarchymal models with predictive validity is the reproduction
of a time course of the “therapeutic effects.”
Furthermore, in most studies drugs are given intraperi-
toneally (IP) instead of orally,although the oral admin-
istration provides several advantages: (i) it mimics the
clinical situation, where most patients take the drug
orally; (ii) drugs taken orally produce metabolite con-
centrations that differ from those obtained after IP or
intravenous (IV) administration; and (iii) it minimizes
the uncontrollable stress effects of injections.
Also, little attention has so far been paid to potential
species-specific differences in the metabolism of the
applied drugs and their dosages.To exclude the effects
of sub- or supraeffective doses there is an urgent need
for monitoring the concentrations of circulating antide-
pressants and their pharmacologically active metabolites
in the animals to be tested in the studies.Equally impor-
tant is the observation that the drug effects are seen at
clinically relevant doses that do not produce other,
potentially confounding effects on physiology and
behavior.
34
The clinical requirement for chronic treatment regimes
has produced extensive literature describing the effects
of chronic antidepressant treatment in normal animals
without paying attention to the basal state of targeted
neural systems.Administration of antidepressant med-
ication, or electroconvulsive stimulation, to nonde-
pressed humans almost certainly does not elicit the same
neural changes as when applied to a depressed patient.
Therefore, we should make sure that the basal state of
laboratory animals undergoing trials of (putative) anti-
depressants closely mirrors what is known about the
neural changes that occur in depressed humans.
As outlined above, the ideal model should respond to
chronic,but not acute,treatment with conventional anti-
depressants.The importance of this feature should not be
underestimated,since only when a model shows a grad-
ual response reflecting a drug’s gradual onset of action is
it possible to detect the actual time point of the thera-
peutic onset.Two models for which the clearest evidence
for gradual onset of action has been obtained are the
chronic mild stress model and the social stress/resident-
intruder paradigm.
It is well known that the environment plays an important
role in determining behavior and,eg,lighting conditions
and familiarity of the experimental settings have a pro-
found impact on the behavior that an experimental ani-
mal displays.Therefore,it is a major problem that in the
laboratory,the “daytime”when an animal’s behavior is
observed is determined purely by the experimenter.It is
quite frequently neglected that laboratory rodents are
nocturnal,and thus generally quiescent during the light
phase of the day.Therefore,in rodents determination of
the effect of psychotropic drugs on natural action pat-
terns of behavior should be performed during the dark
phase of the light-dark cycle.This means that animals
must be housed under a reversed light-dark schedule.
34
Glucocorticoids and depression
Major depressive disorder is a complex, multifactorial
and heterogeneous mental disorder
9 and its phenotypic
heterogeneity requires the development of “multi-phe-
nomenon” animal models.As an example of problem-
atic clinical heterogeneity and its impact upon the util-
ity of animal modeling, we will briefly discuss the
hypothesis of hypercortisolism that has been widely con-
sidered as one of the fundamental neurobiological
abnormalities of depression,and thus has dominated the
relevant literature for many years.
If we are developing or using a valid animal model
based upon perturbed corticosteroid function as a core
aspect of depression, we must be confident that such
perturbation is a reliable feature of the clinical pre-
sentation of depression.However,the clinical situation
reveals that depressed subjects show a remarkable het-
erogeneity of neuroendocrine functions and that
patients with hypothalamo–pituitary–adrenal (HPA)
axis hyperactivity during acute depression may be in
the range of only 35%.
35 Interestingly,hypercortisolism
has also been described in patients with quite different
diagnoses such as Alzheimer’s disease
36 or substance
abuse.
37
A recent study by Strickland et al
38 in women revealed
that, although well-defined adverse life events were
associated with increased cortisol concentrations in
saliva, depression was not. In light of these and other
findings in patients,Matthews et al
35 posed the question
of the validity and relevance of studies modeling depres-
sion in animals with the focus predominantly on corti-
costeroid function and regulation. However, although
these data are not incompatible with the theory that
stress predisposes to depression through its effects on
the HPA axis, one cannot exclude that pre-existing
HPA-axis abnormalities represent a contributory factor
in the genesis of some forms of depression.
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Anxiety enables the individual to recognize danger and
to deal with an unknown or vague internal or external
threat.Fear is a similar alerting signal,but differs from
anxiety in that it is regarded as response to a known,def-
inite,nonconflictual threat.Clinicians assessing anxiety
distinguish between “normal”and “pathological”anxi-
ety. Normal anxiety is an advantageous response to a
threatening situation that accompanies many aspects of
daily life. By contrast, pathological anxiety is an inap-
propriate response to an external or internal stimulus.
In light of the high complexity of anxiety disorders and
the comorbidity with MDD,the chance of succeeding in
developing comprehensive animal models that accurately
reflect the relative influences of contributing factors in
humans is probably quite poor.
39 However,as outlined
below, ample opportunity exists to better define and
extend existing models and to develop new experimen-
tal setups that consider the impact of combined factors
in determining anxious behavior.The examples summa-
rized in this part of the article have been selected because
they model cardinal symptoms of anxiety but not depres-
sive disorders.
Validity criteria for animal models of anxiety disorders
Numerous procedures with experimental animals have
been developed to facilitate preclinical research on the
behavioral pharmacology of anxiety and,as a result of
this aim,are often referred to as “animal models of anx-
iety.”This is an unfortunate error in terminology,not only
because it implies that anxiety is a unitary emotional
state,but also because of the apparent inability of many
tests to consistently detect the anxiolytic effects of novel
drugs.
40The discovery of benzodiazepines (BZs) about
50 years ago,and their therapeutic and commercial suc-
cess in the treatment of anxiety,has stimulated the devel-
opment of a number of experimental test procedures.
Because BZs were the only effective anxiolytic drugs at
that time,the predictive validity of the animal models has
been mainly based on their ability to detect the pharma-
cological action of BZs and related compounds.Later,
clinicians discovered that patients can become addicted
to BZ,and consequently paid more attention to non-ben-
zodiazepine anxiolytics.However,it turned out that these
new drugs were a challenge to the validity of the existing
screening models.The best known example is buspirone,
a clinically effective serotonin (5-HT)1A receptor partial
agonist whose anxiolytic potential was missed by con-
ventional screening procedures in animals,in particular
conflict tests in rats,and was only recognized during clin-
ical assessments for possible antipsychotic efficacy.
41This
was the time when unconditioned conflict tests such as
the elevated plus-maze were developed.
42
A further complication appeared when it became evident
that anxiety is not a unitary phenomenon,but could be
divided into various forms including “normal”or “state”
anxiety on the one hand and “pathological” or “trait”
anxiety on the other hand.According to today’s termi-
nology, pathological anxiety should not be considered
just as an excess of normal anxiety,but it rather appears
that the pathological forms have a different neurobio-
logical basis.Furthermore,the various forms of human
anxiety disorders have been shown to be differentially
sensitive to pharmacological treatment.
Most of the experimental paradigms involve exposure of
animals to external stimuli (eg, cues paired with foot
shock,bright light for rodents,or exposure to a predator)
or internal stimuli (eg,drugs) that are assumed to induce
anxiety.Because none of these models involves patho-
logical anxiety,that is an anxiety-like state independent
of an obvious (external) stimulus,Lister
43 described them
as animal models of state anxiety.In these experimental
set-ups,subjects experience normal anxiety at a particu-
lar moment in time and their emotional state is just
potentiated by an external anxiogenic stimulus.
Despite these problems in the use of animals to study
anxiety,these models have been,and are still,indispens-
able for neurobiological/neuropharmacological research.
Much of our understanding of the neural substrates of
anxiety has emerged from studies employing animal
models that emulate aspects of the presumed etiology,
physiology,and behavioral expression of fear and anxi-
ety.There are several excellent book chapters and review
articles describing and discussing extensively these mod-
els.
2,39,40,43-46 However,a survey of current literature reveals
a confusing diversity of experimental procedures with
more than 30 behavioral paradigms claiming face,con-
struct,and/or predictive validity as animal models of anx-
iety disorders (for review see refs 47-49).
Models for normal anxiety 
An overview of the existing models for normal anxiety is
given in Figure 1.As proposed by Griebel
47 these models
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327are distinguished according to the following categories:
(i) Models based on unconditioned responses; and (ii)
models based on conditioned responses.The first cate-
gory is further divided into four subgroups:models based
on exploratory behavior in rodents (eg, elevated plus-
maze and the light-dark test), models based on social
behavior in rodents (social interaction test) or in non-
human primates (human threat), and models based on
somatic stress reactions (eg,stress-induced hyperthermia).
In the fourth group, other paradigms are summarized
which do not fit easily into the other subgroups such as
the anxiety/fear test battery.
Elevated plus-maze
Today, the majority of studies using animal models of
normal or state anxiety employ unconditioned-based
procedures that rely on the natural behavior of the ani-
mals.Among these,the elevated plus-maze has become
one of the most popular behavioral tests.
42,48 Its popular-
ity is mainly due to practical reasons, because the ele-
vated plus-maze permits a quick screening of potential
anxiety-modulating drugs or of genetically modified lab-
oratory rodents without training the animals or involve-
ment of complex schedules.
48The elevated maze consists
of two opposite open and two closed alleys.When the
animal is taken straight from its home cage it explores
the different alleys and the total number of entries is
counted.Anxiolytics help to overcome the fear-induced
inhibition of open-alley exploration, while anxiogenic
agents suppress open-alley exploration.Unfortunately,
the plus-maze behavior patterns may be influenced by
variations in test parameters that are not always obvious,
eg,the species or strain investigated,housing conditions,
Pharmacological aspects
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Figure 1. Classification of the existing animal models for normal or state anxiety.
46,47 For reasons of clarity, models are placed into one of the fol-
lowing two categories: Tests based on unconditioned responses and tests based on conditioned responses. Tests described in this arti-
cle are marked by •. 
Animal
models
of normal
anxiety
Models based on 
unconditioned 
responses
Models based
on conditioned 
responses
Models based on social behavior
• Social interaction test
- Social competition
- Human threat?
- Ultrasonic distress
Miscellaneous
- Anxiety test battery - Marble-burying
Conflict tests
- Geller-Seifter
- Pigeons and monkeys conflict
- Vogel
Miscellaneous
• Fear potentiated startle reflex
- Shock-probe burying test
- Conditioned taste aversion
- Active/passive avoidance
- Conditioned emotional response
Stress-induced modifications of behavioral and / or
physiological responses
- Consummatory behavior
- Thermic response
- Corticosterone response
- Colonic motor response
- Defecation 
- Micturition
Models based on exploration
• Elevated plus maze
• Zero maze
• Open field
- Hole board
- Light/dark test
- Staircase test
- Free exploration testAnimal models of depression and anxiety - Fuchs and Flügge Dialogues in Clinical Neuroscience - Vol 8 . No.3 . 2006
329
day time of the testing,intensity of the light,and scoring
method.
50As a result,a vast number of studies employ-
ing the elevated plus-maze have yielded inconsistent
findings. To overcome these problems, Rodgers and
Johnson
51 have developed an “ethological”version of the
mouse plus-maze that incorporates species-specific
behavioral postures (eg,risk assessment,head-dipping)
together with the conventional spatiotemporal measures
of open-arm avoidance.
Elevated zero maze 
This is a recent modification of the plus-maze designed
for investigations in mice.It is an elevated annular plat-
form with two opposite open and two closed quadrants.
Animals are placed in one of the closed quadrants des-
ignated as the starting quadrant and anxiety related
behaviors are recorded by both the observer and through
a video system.
Open field test
Rodents are night-active animals that prefer darkness
and avoid bright areas.This has to be taken into account
when using the open field test,a very common observa-
tional method.
52 For the open field test, the animal is
taken from its home cage and placed in a novel and rel-
atively lit arena that is large enough for the animal to
move around in.The area is divided into peripheral and
central units, and locomotion and rearing can be
recorded in these units.Because of its photophobicity,the
animal avoids the brightly lit open spaces and prefers to
stay close to the walls.Exploratory or locomotor behav-
ior is therefore measured while determining the distance
from the wall,and autonomic activity such as urination
and defecation is evaluated. By using infrared beam
array systems,locomotion,rearing and time spent in cer-
tain predefined areas of the open field are measured
automatically.One also has to consider that the behavior
displayed in the open field—similar to that in the ele-
vated plus maze—is remarkably sensitive to a variety of
internal and external factors.
Social interaction test
The social interaction test that was originally introduced
by File,
53 and that quantifies the level of social behavior
between animals,is a valuable behavioral paradigm for
testing anxiolytic drugs.Experimental animals unfamil-
iar to each other are placed in pairs into an open arena.
When the arena is brightly illuminated the situation is
aversive for the animals,so that they reduce their social
interactions.Anxiolytics usually increase the time spent
in social interactions.
Fear-potentiated startle test
Davis and colleagues
54 have utilized the fear-potentiated
startle test to study the fear circuitry in the brain.This test
includes a classical fear conditioning in that a stimulus
(eg,light) is paired with a mild electric foot shock.During
the fear-conditioning phase a light stimulus signals the
occurrence of a shock.The startle response is elicited by
a loud noise,and its amplitude is augmented when the
light and the noise are presented together.BZs have anx-
iolytic effects in this paradigm in that they inhibit the
enhancement of the startle response but do not block the
startle response per se. Briefly, the paradigm involves
placing the animal in a cage equipped to measure the
amplitude of the startle response elicited by the noise,
either in the presence or absence of a light previously
paired with an electric shock.Animals that have already
been exposed to the shock-paired light show a greater
startle response to the noise in the presence of the light
than in its absence.Using this kind of potentiated startle
response as an operational measure,it was found that the
central nucleus of the amygdala and a variety of hypo-
thalamic and brain stem areas are involved in physiolog-
ical (eg,activation of the sympathetic and the parasym-
pathetic system, release of “stress hormones”) and
behavioral responses (eg,changes in locomotor activity,
freezing) that reflect fear and anxiety.
54,55
Defense tests
Defensive behaviors in mammals are thought to constitute
a significant parameter that can be studied to understand
human emotional disorders, including anxiety.
56 These
behaviors occur in response to a number of threatening
stimuli including predators,attacks by conspecifics,or pres-
ence of dangerous objects.The mouse defense test battery
(MDTB) consists of an oval runway that allows the inves-
tigation of state anxiety by extensive ethological analyses
to generate comprehensive behavioral profiles following
drug treatment.
57,58 Specific situational and behavioral com-
ponents of the anxiety defense test battery,including reac-tivity to stimuli associated with potential threat such as
presentation of an anesthetized predator (a rat),are incor-
porated into the MDTB.Drug experiments have demon-
strated that anxiolytic compounds generally tend to
decrease defensive behaviors.It is noteworthy that some
responses are specifically or mainly modulated by certain
classes of drugs,and it has been suggested that risk assess-
ment,flight,defensive threat/attack and escape attempts
probably reflect different aspects of anxiety-related reac-
tions.
59 These tests may thus represent a considerable
methodological improvement because a major concern
with traditional animal models of state anxiety that are
based on single measures is that they are often unable to
discriminate between effects of different classes of anxi-
olytics (benzodiazepines,5-HT1A agonists,5-HT reuptake
inhibitors),whereas clinical findings strongly indicate dif-
ferential therapeutic efficacy of these agents.Based on pre-
sent observations in mice,the ethological plus-maze and
the MDTB provide new tools to differentiate anxiolytic
drugs of various classes that induce specific behavioral
profiles.
Animal models for pathological anxiety
Pathological anxiety in humans is often an enduring fea-
ture of the individual,at least in part due to a genetic pre-
disposition.To model genetically based anxiety,mice with
target mutations in distinct genes were created that
exhibit phenotypic changes indicative of increased anxi-
ety.In addition rat or mouse lines were bred to select for
high or low emotional reactivity.
The neurotransmitter 5-HT is centrally involved in the
neuropathology of many neuropsychiatric disorders.
More than a dozen pharmacologically distinct serotonin
receptor subtypes regulate a wide range of functions in
different brain areas and in the periphery of the body
(for review, see ref 60). There is pharmacological and
neuroanatomical evidence that at least one 5-HT recep-
tor,5-HT1A,is involved in the regulation of anxiety-like
behaviors.
49,61 Results of recent studies employing mutant
mice with targeted deletions of the 5-HT1A receptor gene
further support a role of this receptor in anxiety.
62 5-HT1A
receptor null mutant mouse lines have been indepen-
dently generated in three laboratories from mice with
different genetic backgrounds, C57BL/6,
63 129/Sz,
62 or
through outbreeding from Swiss-Webster.
64 Given the
interlaboratory variability that occurred in other cases of
behavioral studies on genetically modified mice,
65 it is
notable that concordant findings on 5-HT1A receptor null
mutants were reported in all three laboratories and
across the three mouse strains.
Further examples of models for pathological anxiety are
mice that were gene targeted for the corticotropin-releas-
ing factor (CRF)
66 or for the γ2 subunit of the GABAA
receptor.This receptor subunit is known to be essential in
mediating the anxiolytic actions of benzodiazepines.
67An
“anxious”phenotype was also observed in mutant mice
lacking the gene for the neuroactive peptide NPY 
68;(see
also the review on genetic models of anxiety).
69
At first glance,these lines of mutant mice seem to provide
a unique opportunity to model pathological or trait anxi-
ety.Moreover,compared with the state anxiety models in
which the baseline level of anxiety of a subject is increased
artificially by exposure to external (aversive) stimuli,the
new models seem to be advantageous in that they may
represent a kind of “general anxiety” due to a certain
genetic modification.This sounds reasonable since genetic
studies in humans have indicated that there are genetic
components contributing to the development of anxiety
disorders.However,one has to consider that in humans,
the modulation of anxiety processes involves multiple
genes.In the future,the use of mice strains that display ele-
vated emotionality due to a distinct “genetic background,”
or mice selected for their high levels of anxiety using gene
targeting experiments may lead to greater progress in our
understanding of the neurobiological substrates of anxi-
ety. Such animals would exhibit increased anxiety not
because of a defect in a single gene,but because of a com-
plex set of genes that result in an enduring feature of the
strain/individual,thus determining its phenotype in com-
bination with environmental factors.
46
Inbred strains which show constantly high levels of anx-
iety/fearfulness have already been created.In mice,the
BALB/c strain has been considered to be a realistic
model of trait anxiety,which is probably not related to
only one particular target gene but to abnormalities in
various neurotransmitter circuits such as the
GABAergic,dopaminergic and the opioid system.
46Also
in rats, several strains of trait anxiety have been
described,eg,the Maudsley rat,
70 the Wistar–Kyoto,
71 the
Roman,
72 or the Sardinian alcohol-preferring line.
73
Recently, two breeding lines were generated from the
same strain of Wistar rats showing a maximum difference
in anxiety-related behavior and a minimum difference in
other behaviors as well as in physiological parameters
not directly related to anxiety.These two rat lines are
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330now called high anxiety-related behavior (HAB) and low
anxiety-related behavior (LAB).
74Their overall perfor-
mance in various behavioral tests suggests that selective
breeding has resulted in lines not only differing markedly
in their innate anxiety-related behavior but also in stress-
related behavioral performances,indicating a close link
between the emotional evaluation of a novel and stress-
ful situation and a subject's capability to cope with such
situations.
Developing novel models relevant to 
depression and anxiety disorders
One striking aspect of most anxiety disorders and MDD
is the higher incidence in females compared with males.
9
Furthermore, gender differences in psychotropic drug
metabolism and clearance can have direct effects on the
efficacy of pharmacological treatments of mental disor-
ders in women.
75Thus,biological,hormonal,and cultural
factors may contribute to gender differences in some dis-
orders and to gender-specific efficacy of pharmacologi-
cal interventions.Basic research in animals may help to
determine the degree to which these features are caused
by differences in brain physiology.
76 Given the prepon-
derance of sex differences in many aspects of anxiety dis-
orders and MDD,it is surprising to find how few basic
animal studies have considered gender as a determining
factor for depression and anxiety disorders.A recent sur-
vey revealed that approximately 90% of the animal stud-
ies on serotonergic drugs and anxiety-like behaviors uti-
lized males exclusively.
77 Clearly,this major deficiency has
delayed progress towards an understanding of the
processes contributing to anxiety disorders and MDD,
and most likely hindered the development of gender-spe-
cific treatments.
Conclusion
In conclusion,animal models are indispensable tools for
research on the neurobiological mechanisms underlying
MDD and/or anxiety disorders and for the development
of new antidepressant/anxiolytic drugs.However,besides
the obvious progress in research that could only be
achieved because of the existence of these models,one
also has to bear in mind that each animal model has its
pros and cons.Currently,it appears that the use of sev-
eral models,either successively or in parallel,provides
the greatest chance to elucidate the neurobiological
processes of psychiatric diseases and to identify new,
effective antidepressant and anxiolytic compounds. ❏
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Modelos experimentales de animales para la
simulación de depresión y ansiedad
Hoy en día existe un gran número de modelos ani-
males para evaluar la depresión y la ansiedad. Sin
embargo, la relación entre estos modelos y los sín-
dromes clínicos de depresión y ansiedad no siempre
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o/y otros problemas psiquiátricos, la posibilidad de
crear modelos animales que reflejen consistente-
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utilizan modelos animales para intentar compren-
der las semejanzas entre la conducta animal y
humana, se debe considerar el contexto en el cual
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relevantes de los trastornos de ansiedad patológica
y de la depresión se requiere de una aproximación
pragmática que combine esfuerzos preclínicos y clí-
nicos. Los modelos resultantes pueden identificar
procesos del sistema nervioso central que regulan
la producción de una conducta definida, con la
posibilidad de desarrollar tratamientos más efecti-
vos. 
Modèles animaux expérimentaux pour
simuler la dépression et l’anxiété
Il existe aujourd’hui un grand nombre de modèles
animaux pour évaluer la dépression et l’anxiété.
Les relations entre ces modèles et les syndromes cli-
niques de dépression et d’anxiété ne sont cepen-
dant pas toujours claires. La possibilité de créer des
modèles animaux imitant avec validité les troubles
anxieux est assez faible, puisque ces troubles sont
multifactoriels, se présentant fréquemment en
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chopharmacologie. Une approche pragmatique
combinant les thèmes précliniques et cliniques est
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